Mylan Launches US Advair Rival, Wixela Inhub, At A 70% Discount

Mylan has launched its Wixela Inhub rival to GSK’s Advair Diskus at a 70% discount to the brand price.

Girl
Mylan Can Breathe Easy After Getting Wixela Inhub To Market • Source: Shutterstock

All three strengths of Mylan’s Wixela Inhub (fluticasone/salmeterol) generic rival to GlaxoSmithKline’s (GSK’s) Advair Diskus are now available in the US at a 70% discount to the brand, the generics firm has announced.

“The wholesale acquisition costs of Wixela Inhub 100μg/50μg, 250μg/50μg and 500μg/50μg are US$93.71, US$116.44 and US$153

More from Generics

More from Products